Top ▲
Gene and Protein Information  |
||||||
| Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
| Human | - | 477 | 11q22.2 | MMP3 | matrix metallopeptidase 3 | |
| Mouse | - | 477 | 9 2.46 cM | Mmp3 | matrix metallopeptidase 3 | |
| Rat | - | 475 | 8q11 | Mmp3 | matrix metallopeptidase 3 | |
| Previous and Unofficial Names |
| transin-1 | PTR1 protein | SL-1 | progelatinase | SLN1 | Str1 | STMY1 | matrix metallopeptidase 3 (stromelysin 1, progelatinase) |
| Database Links |
|
| Specialist databases | |
| MEROPS | M10.005 (Hs) |
| Other databases | |
| Alphafold | P08254 (Hs), P28862 (Mm), P03957 (Rn) |
| BRENDA | 3.4.24.17 |
| CATH/Gene3D | 2.110.10.10, 3.40.390.10 |
| ChEMBL Target | CHEMBL283 (Hs) |
| DrugBank Target | P08254 (Hs) |
| Ensembl Gene | ENSG00000149968 (Hs), ENSMUSG00000043613 (Mm), ENSRNOG00000032626 (Rn) |
| Entrez Gene | 4314 (Hs), 17392 (Mm), 171045 (Rn) |
| Human Protein Atlas | ENSG00000149968 (Hs) |
| KEGG Enzyme | 3.4.24.17 |
| KEGG Gene | hsa:4314 (Hs), mmu:17392 (Mm), rno:171045 (Rn) |
| OMIM | 185250 (Hs) |
| Pharos | P08254 (Hs) |
| RefSeq Nucleotide | NM_002422 (Hs), NM_010809 (Mm), NM_133523 (Rn) |
| RefSeq Protein | NP_002413 (Hs), NP_034939 (Mm), NP_598207 (Rn) |
| UniProtKB | P08254 (Hs), P28862 (Mm), P03957 (Rn) |
| Wikipedia | MMP3 (Hs) |
| Enzyme Reaction |
||||
|
||||
Download all structure-activity data for this target as a CSV file 
| Inhibitors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Immunopharmacology Comments |
| MMP3 is included in GtoImmuPdb based on its reported involvement in inflammatory diseases. |
| Immuno Disease Associations | ||||||||||
|
||||||||||
|
||||||||||
|
| Clinically-Relevant Mutations and Pathophysiology
|
||||||||||||
|
||||||||||||
1. Fiedorczyk M, Klimiuk PA, Sierakowski S, Gindzienska-Sieskiewicz E, Chwiecko J. (2006) Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis. J Rheumatol, 33 (8): 1523-9. [PMID:16881109]
2. Fray MJ, Dickinson RP. (2001) Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1). Bioorg Med Chem Lett, 11 (4): 571-4. [PMID:11229774]
3. Green MJ, Gough AK, Devlin J, Smith J, Astin P, Taylor D, Emery P. (2003) Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxford), 42 (1): 83-8. [PMID:12509618]
4. Juran BD, Atkinson EJ, Schlicht EM, Larson JJ, Ellinghaus D, Franke A, Lazaridis KN. (2011) Genetic polymorphisms of matrix metalloproteinase 3 in primary sclerosing cholangitis. Liver Int, 31 (6): 785-91. [PMID:21134112]
5. Nuti E, Casalini F, Santamaria S, Gabelloni P, Bendinelli S, Da Pozzo E, Costa B, Marinelli L, La Pietra V, Novellino E et al.. (2011) Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors. Eur J Med Chem, 46 (7): 2617-29. [PMID:21514700]
6. Orbe J, Rodríguez JA, Sánchez-Arias JA, Salicio A, Belzunce M, Ugarte A, Chang HC, Rabal O, Oyarzabal J, Páramo JA. (2015) Discovery and safety profiling of a potent preclinical candidate, (4-[4-[[(3R)-3-(hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]-N-methylbenzamide) (CM-352), for the prevention and treatment of hemorrhage. J Med Chem, 58 (7): 2941-57. [PMID:25686022]
7. Pender SL, Croucher PJ, Mascheretti S, Prothero JD, Fisher SA, MacDonald TT, Schreiber S, Ye S. (2004) Transmission disequilibrium test of stromelysin-1 gene variation in relation to Crohn's disease. J Med Genet, 41 (9): e112. [PMID:15342709]
8. Pender SL, Tickle SP, Docherty AJ, Howie D, Wathen NC, MacDonald TT. (1997) A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol, 158 (4): 1582-90. [PMID:9029093]
9. Rasmussen HS, McCann PP. (1997) Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther, 75 (1): 69-75. [PMID:9364582]
10. Takeuchi T, Hayashi M, Tamita T, Nomura Y, Kojima N, Mitani A, Takeda T, Hitaka K, Kato Y, Kamitani M et al.. (2022) Discovery of Aryloxyphenyl-Heptapeptide Hybrids as Potent and Selective Matrix Metalloproteinase-2 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis. J Med Chem, 65 (12): 8493-8510. [PMID:35687819]
11. Troeberg L, Nagase H. (2012) Proteases involved in cartilage matrix degradation in osteoarthritis. Biochim Biophys Acta, 1824 (1): 133-45. [PMID:21777704]
12. Yamamoto M, Tsujishita H, Hori N, Ohishi Y, Inoue S, Ikeda S, Okada Y. (1998) Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket. J Med Chem, 41 (8): 1209-17. [PMID:9548812]
M10: Matrix metallopeptidase: MMP3. Last modified on 12/07/2022. Accessed on 15/06/2025. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1630.
target has curated data in GtoImmuPdb
